DBV Technologies Reports Full Year 2025 Financial Results and Business Update

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• BLA submission for 4-7 year olds anticipated in the first half of 2026 with potential for Priority Review

  60% confidence

• Cash and cash equivalents are sufficient to fund operations into the second quarter of 2027

  60% confidence

• Completion of enrollment of COMFORT Toddlers safety study and subsequent topline results readout expected in 2026

  60% confidence

• Our focus on bringing the VIASKIN Peanut Patch to peanut-allergic children ages 1-7 years remains unwavering

  60% confidence

• I am pleased with our progress to date in enhancing DBV's capabilities and building a company ready for launch

  60% confidence

• We entered 2025 with a clear set of priorities – strengthening our financial position, advancing our clinical development program (including completing VITESSE and initiating COMFORT Toddlers), and preparing for the BLA submission and commercialization of the VIASKIN Peanut Patch in the United States, if approved

  60% confidence

• BLA submission for 1-3 year olds anticipated in the second half of 2026 under an Accelerated Approval Pathway

  60% confidence

Cited in these Via News reports

• Wave Life Sciences Obesity Trial Shows Baseline BMI Gaps Skew Efficacy Data Across Global Drug Race →